Show simple item record

dc.contributor.authorLaPointe, Lawrence C
dc.contributor.authorPedersen, Susanne K
dc.contributor.authorDunne, Robert
dc.contributor.authorBrown, Glenn S
dc.contributor.authorPimlott, Letitia
dc.contributor.authorGaur, Snigdha
dc.contributor.authorMcEvoy, Aidan
dc.contributor.authorThomas, Melissa
dc.contributor.authorWattchow, David Anthony
dc.contributor.authorMolloy, Peter L
dc.contributor.authorYoung, Graeme Paul
dc.date.accessioned2013-08-06T05:57:05Z
dc.date.available2013-08-06T05:57:05Z
dc.date.issued2012-01-19
dc.identifier.citationLaPointe, L.C., Pedersen, S.K., Dunne, R., Brown, G.S., Pimlott, L., Gaur, S., McEvoy, A., Thomas, M., Wattchow, D., Molloy, P.L. and Young, G.P., 2012. Discovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testing. PLoS ONE 7(1): e29059.en
dc.identifier.issn1932-6203
dc.identifier.urihttp://hdl.handle.net/2328/26899
dc.description.abstractResults: Genome-wide analysis uncovered reproducible gene expression signatures for both adenomas and cancers compared to controls. 386/489 (79%) of the adenoma and 439/529 (83%) of the adenocarcinoma biomarkers were validated in independent tissues. We also identified genes differentially expressed in adenomas compared to cancer. KIAA1199 was selected for further analysis based on consistent up-regulation in neoplasia, previous studies and its interest as an uncharacterized gene. Plasma KIAA1199 RNA levels were significantly higher in patients with either cancer or adenoma (31/ 40) compared to neoplasia-free controls (6/20).en
dc.description.sponsorshipThis work was co-funded by Flinders University of South Australia and the Commonwealth Scientific and Industrial Research Organisation (CSIRO) of Australia. Drs. Dunne, Molloy and Brown are employed by CSIRO. These funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Funding was also provided by Clinical Genomics Pty Ltd., a company involved in the discovery and commercialization of biomarkers for colorectal cancer. Drs. LaPointe, Pedersen, Gaur, McEvoy and Thomas are employed by Clinical Genomics Pty Ltd and Prof. Young is a paid consultant of Clinical Genomics Pty Ltd. The funder thus played roles in study design, data collection and analysis, decision to publish, and preparation of the manuscript. Mrs. Pimlott and Dr. Wattchow have nothing to disclose. This work was co-funded by Clinical Genomics Pty Ltd, a company involved in the discovery and commercialization of biomarkers for colorectal cancer. Drs. LaPointe, Pedersen, Gaur, McEvoy and Thomas are employed by Clinical Genomics Pty Ltd. Prof. Young is a paid consultant of Clinical Genomics Pty Ltd. This does not alter the authors’ adherence to all the PLoS ONE policies on sharing data and materials.en
dc.language.isoen
dc.publisherPublic Library of Scienceen
dc.relationhttp://purl.org/au-research/grants/NHMRC/1006242en
dc.rightsThis is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.en
dc.subjectColorectal canceren
dc.subjectBiomarker validationen
dc.titleDiscovery and validation of molecular biomarkers for colorectal adenomas and cancer with application to blood testingen
dc.typeArticleen
dc.relation.grantnumberNHMRC/1006242en
dc.identifier.doihttps://doi.org/10.1371/journal.pone.0029059en
dc.rights.holder(C) 2012 LaPointe et al.en
dc.rights.licenseCC-BY


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record